Bicycle Therapeutics Stock News

Following recent updates from numerous management teams within the health care space, Needham analyst Ami Fadia has reevaluated the stocks in the firm's coverage universe using a stock selection crit

Bicycle Therapeutics plc (NASDAQ:BCYC)s stock price gapped down before the market opened on Thursday after an insider sold shares in the company. The stock had previously closed at $59.25, but opened at $57.99. Bicycle Therapeutics shares last traded at $59.92, with a volume of 794 shares traded. Specifically, CEO Kevin Lee sold 4,631 shares of []

SVB Leerink started coverage on shares of Bicycle Therapeutics (NASDAQ:BCYC) in a report issued on Friday, Price Targets.com reports. The brokerage issued an outperform rating and a $70.00 price objective on the stock. A number of other equities analysts also recently issued reports on BCYC. Canaccord Genuity lifted their price objective on shares of Bicycle []

Needham & Company LLC started coverage on shares of Bicycle Therapeutics (NASDAQ:BCYC) in a research report report published on Thursday, Price Targets.com reports. The firm issued a buy rating and a $85.00 price target on the stock. Other research analysts also recently issued reports about the stock. HC Wainwright restated a buy rating and set []

Research analysts at Needham & Company LLC initiated coverage on shares of Bicycle Therapeutics (NASDAQ:BCYC) in a report issued on Thursday, Analyst Price Targets reports. The firm set a buy rating and a $85.00 price target on the stock. Needham & Company LLCs price objective suggests a potential upside of 62.84% from the stocks previous []

Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) have been given an average rating of Buy by the nine analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month target price among brokers that []

The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples.

Bicycle Therapeutics (NASDAQ:BCYC) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends. Analyst Ratings This is a summary of recent ratings and price targets for Bicycle Therapeutics and []

Wall Street analysts forecast that Bicycle Therapeutics plc (NASDAQ:BCYC) will announce sales of $5.69 million for the current quarter, according to Zacks. Six analysts have made estimates for Bicycle Therapeutics earnings, with the highest sales estimate coming in at $16.67 million and the lowest estimate coming in at $1.79 million. Bicycle Therapeutics reported sales of []

Related Stocks: RGEN , AHCO , BCYC ,

Related Stocks: INBX , IMTX , CMPS , GOSS , BCAB , CRVS , BCYC , APLS , ZNTL , AYLA , WVE , MCRB , ALEC , ANVS , CGEM , CCXI , CHAQ.U , IMAB ,

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl

Bicycle Therapeutics: Platform Technology Has Potential; Move To Combination Therapy With Opdivo Is Next

The stock price of Bicycle Therapeutics PLC (NASDAQ: BCYC) increased by over 22% this past week. This is why it happened.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl